Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene

Pharmacogenomics Journal

Volumn 13, Issue 3, 2013, Pages 272-279

  Chowdhury, N I ^a   Tiwari, A K ^a   Souza, R P ^b   Zai, C C ^a   Shaikh, S A ^a   Chen, S ^a   Liu, F ^a   Lieberman, J A ^c   Meltzer, H Y ^d   Malhotra, A K ^e   Kennedy, J L ^a   Muller D J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b Laboratory of Neurosciences   (Brazil)

^c Columbia University ^*  (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Association study; clozapine; electrophoretic mobility shift assays; MC4R; pharmacogenetics; weight gain

Indexed keywords

ALANINE; GLYCINE; MELANOCORTIN 4 RECEPTOR; NEUROLEPTIC AGENT; TRANSCRIPTION FACTOR;

ADULT; ARTICLE; BINDING SITE; CLINICAL EVALUATION; DRUG EFFECT; DRUG SAFETY; EUROPE; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE FUNCTION; GENE LOCATION; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MELANOCORTIN 4 RECEPTOR GENE; PRIORITY JOURNAL; PROMOTER REGION; SCHIZOPHRENIA; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; WEIGHT CHANGE; WEIGHT GAIN;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; CLOZAPINE; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, MELANOCORTIN, TYPE 4; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 84878228310     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2011.66     Document Type: Article

References (34)

1. Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M et al. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res 2005; 80: 9-18.
2. Müller DJ, Kennedy JL. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 2006; 6: 863-887.
3. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from III NHANES. Schizophr Res 2005; 8: 19-32.
4. Meyer J, Loh C, Leckband SG, Boyd JA, Wirshing WC, Pierre JM et al. Prevalence of the metabolic syndrome in veterans with schizophrenia. J Psychiatr Pract 2006; 12: 5-10.
5. Callaghan RC, Boire MD, Lazo RG, McKenzie K, Cohn T. Schizophrenia and the incidence of cardiovascular morbidity: a population-based longitudinal study in Ontario, Canada. Schizophr Res 2009; 115: 325-332.
6. Gebhardt S, Theisen FM, Haberhausen M, Heinzel-Gutenbrunner M, Wehmeier PM, Krieg JC et al. Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study. J Clin Pharm Ther 2010; 35: 207-211.
7. Wang Y, Lobstein T. Worldwide trends in childhood overweight and obesity. Int J Pediatr Obes 2006; 1: 11-25.
8. Santini F, Maffei M, Pelosini C, Salvetti G, Scartabelli G, Pinchera A. Melanocortin-4 receptor mutations in obesity. Adv Clin Chem 2009; 48: 95-109.
9. Arch JR. Central regulation of energy balance: inputs, outputs and leptin resistance. Proc Nutr Soc 2005; 64: 39-46.
10. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR et al. Targeted disruption of the melanocortion-4 receptor results in obesity in mice. Cell 1997; 88: 131-141.
11. He S, Ye Z, Dobbelaar PH, Bakshi RK, Hong Q, Dellureficio JP et al. Discovery of highly potent and efficacious MC4R agonists with spiroindane N-Me-1, 2, 4-triazole privileged structures for the treatment of obesity. Bioorg Med Chem Lett 2010; 20: 6524-6532.
12. Srisai D, Gillum MP, Panaro BL, Zhang XM, Kotchabhakdi N, Shulman GI et al. Characterization of the hyperphagic response to dietary fat in the MC4R knockout mouse. Endocrinology 2011; 152: 890-902.
13. Vaisse C, Clement K, Guy-Grand B, Froguel P. A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nat Genet 1998; 20: 113-114.
14. Loos RJ, Lindgren CM, Li S, Wheeler E, Zhao JH, Prokopenko I et al. Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet 2008; 40: 768-775.
15. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU et al. Association analyses of 249 796 individuals reveal 18 new loci associated with body mass index. Nat Genet 2010; 42: 937-948.
16. Brönner G, Sattler AM, Hinney A, Soufi M, Geller F, Schäfer H et al. The 103I variant of the melanocortin 4 receptor is associated with low serum triglyceride levels. J Clin Endocrinol Metab 2006; 9: 535-538.
17. Heid IM, Vollmert C, Kronenberg F, Huth C, Ankerst DP, Luchner A et al. Association of the MC4R V103I polymorphism with the metabolic syndrome: the KORA Study. Obesity (Silver Spring) 2008; 16: 369-376.
18. Malhotra AK, Correll CJ, Chowdhury NI, Müller DJ, Gregersen PK, Lee AT et al. Common variants near the melanocortin 4 receptor gene are associated with severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry (in press).
19. Tiwari AK, Zai CC, Likhodi O, Lisker A, Singh D, Souza RP et al. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in schizophrenia. Neuropsychopharmacology 2010; 35: 1315-1324.
20. Masellis M, Basile V, Meltzer HY, Lieberman JA, Sevy S, Macciardi FM et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 1998; 19: 123-132.
21. Basile VS, Masellis M, De Luca V, Meltzer HY, Kennedy JL. 759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 2002; 360: 1790-1791.
22. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002; 159: 255-262.
23. Müller DJ, Klempan TA, De Luca V, Sicard T, Volavka J, Czobor P et al. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neurosci Lett 2005; 379: 81-89.
24. Lahiri DK, Nurnberger JI. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991; 19: 5444.
25. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 2003; 25: 115-121.
26. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
27. Gauderman WJ, Morrison JM. 2006. QUANTO 1.1: a computer program for power and sample size calculations for genetic-epidemiology studies. 2007. http://hydra.usc.edu/gxe.
28. Norris RA, Kern MJ. The identification of Prx1 transcription regulatory domains provides a mechanism for unequal compensation by the Prx1 and Prx2 loci. J Biol Chem 2001; 276: 26829-26837.
29. Towler DA, Rutledge SJ, Rodan GA. Msx-2/Hox 8.1: a transcriptional regulator of the rat osteocalcin promoter. Mol Endocrinol 1994; 11: 1484-1493.
30. Nasrallah HA. The urgent need for monitoring and intervention to reduce metabolic risk factors in patients with schizophrenia. CNS Spectr 2008; 13: 5-6.
31. Renström F, Payne F, Nordström A, Brito EC, Rolandsson O, Hallmans G et al. GIANT Consortium. Replication and extension of genome-wide association study results for obesity in 4923 adults from northern Sweden. Hum Mol Genet 2009; 18: 1489-1496.
32. Espinoza CA, Ren B. Mapping higher order structure of chromatin domains. Nat Genet 2011; 43: 615-616.
33. Granell S, Mohammad S, Ramanagoudr-Bhojappa R, Baldini G. Obesity-linked variants of melanocortin-4 receptor are misfolded in the endoplasmic reticulum and can be rescued to the cell surface by a chemical chaperone. Mol Endocrinol 2010; 24: 1805-1821.
34. Beckers S, Zegers D, de Freitas F, Mertens IL, Van Gaal LF, Van Hul W. Association study of MC4R with complex obesity and replication of the rs17782313 association signal. Mol Genet Metab 2011 May; 103(1): 71-75.